Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.

Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG.

Nat Cell Biol. 2018 Sep;20(9):1064-1073. doi: 10.1038/s41556-018-0169-1. Epub 2018 Aug 13.

2.

US immigration order strikes against biotech.

Levin JM, Holtzman SH, Maraganore J, Hastings PJ, Cohen R, Dahiyat B, Adams J, Adams C, Ahrens B, Albers J, Aspinall MG, Audia JE, Babler M, Barrett P, Barry Z, Bermingham N, Bloch S, Blum RI, Bolno PB, Bonney MW, Booth B, Bradbury DM, Brauer SK, Byers B, Cagnoni PJ, Cali BM, Ciechanover I, Clark C, Clayman MD, Cleland JL, Cobb P, Cooper R, Currie MG, Diekman J, Dobmeier EL, Doerfler D, Donley EL, Dunsire D, During M, Eckstein JW, Elenko E, Exter NA, Fleming JJ, Flesher GJ, Formela JF, Forrester R, Francois C, Franklin H, Freeman MW, Furst H, Gage LP, Galakatos N, Gallagher BM, Geraghty JA, Gill S, Goeddel DV, Goldsmith MA, Gowen M, Goyal V, Graney T, Grayzel D, Greene B, Grint P, Gutierrez-Ramos JC, Haney B, Ha-Ngoc T, Harris T, Hasnain F, Hata YS, Hecht P, Henshaw L, Heyman R, Hoppenot H, Horvitz HR, Hughes TE, Hutton WS, Isaacs ST, Jenkins A, Jonker J, Kaplan J, Karsen P, Keiper J, Kim J, Kindler J, King R, King V, Kjellson N, Koenig S, Koenig G, Kolchinsky P, Laikind P, Langer RB, Lee JJ, Leff JS, Leicher BA, Leschly N, Levin A, Levin M, Levine AJ, Levy A, Liu DR, Lodish HF, Lopatin U, Love TW, Macdonald G, Maderis GJ, Mahadevia A, Mahanthappa NK, Martin JF, Martin A, Martucci WE, McArthur JG, McCann CM, McCarthy SA, McDonough CG, Mendlein J, Miller L, Miralles D, Moch KI, More B, Myers AG, Narachi MA, Nashat A, Nelson W, Newell WJ, Olle B, Osborn JE, Owens JC, Pande A, Papadopoulos S, Parker HS, Parmar KM, Patterson MR, Paul SM, Perez R, Perry M, Pfeffer CG, Powell M, Pruzanski M, Purcell DJ, Rakhit A, Ramamoorthi K, Rastetter W, Rawcliffe AA, Reid LE, Renaud RC, Rhodes JP, Rieflin WJ, Robins C, Rocklage SM, Rosenblatt M, Rosin JG, Rutter WJ, Saha S, Samuels C, Sato VL, Scangos G, Scarlett JA, Schenkein D, Schreiber SL, Schwab A, Sekhri P, Shah R, Shenk T, Siegall CB, Simon NJ, Simonian N, Stein J, Su M, Szela MT, Taglietti M, Tandon N, Termeer H, Thornberry NA, Tolar M, Ulevitch R, Vaishnaw AK, VanLent A, Varsavsky M, Vlasuk GP, Vounatsos M, Waksal SG, Warma N, Watts RJ, Werber Y, Westphal C, Wierenga W, Williams DE, Williams LR, Xanthopoulos KG, Zohar D, Zweifach SS.

Nat Biotechnol. 2017 Mar 7;35(3):204-206. doi: 10.1038/nbt.3824. No abstract available.

PMID:
28267733
3.

Reply: High Risk of Gastrointestinal BleedingĀ on Dual Antiplatelet Treatment.

Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators.

J Am Coll Cardiol. 2016 Aug 30;68(9):981-2. doi: 10.1016/j.jacc.2016.06.008. No abstract available.

4.

Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.

Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DL; COGENT Investigators.

Am J Med. 2016 Sep;129(9):1002-5. doi: 10.1016/j.amjmed.2016.03.042. Epub 2016 Apr 30.

PMID:
27143321
5.

Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.

Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators.

J Am Coll Cardiol. 2016 Apr 12;67(14):1661-71. doi: 10.1016/j.jacc.2015.12.068. Epub 2016 Mar 21.

6.

The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.

Vardi M, Cryer BL, Cohen M, Lanas A, Schnitzer TJ, Lapuerta P, Goldsmith MA, Laine L, Doros G, Liu Y, McIntosh AI, Cannon CP, Bhatt DL.

Aliment Pharmacol Ther. 2015 Aug;42(3):365-74. doi: 10.1111/apt.13260. Epub 2015 May 29.

7.

Clopidogrel with or without omeprazole in coronary artery disease.

Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP; COGENT Investigators.

N Engl J Med. 2010 Nov 11;363(20):1909-17. doi: 10.1056/NEJMoa1007964. Epub 2010 Oct 6.

8.

Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo.

Michel N, Goffinet C, Ganter K, Allespach I, Kewalramani VN, Saifuddin M, Littman DR, Greene WC, Goldsmith MA, Keppler OT.

Retrovirology. 2009 Jan 13;6:2. doi: 10.1186/1742-4690-6-2.

9.

Impaired CD8 T cell memory and CD4 T cell primary responses in IL-7R alpha mutant mice.

Osborne LC, Dhanji S, Snow JW, Priatel JJ, Ma MC, Miners MJ, Teh HS, Goldsmith MA, Abraham N.

J Exp Med. 2007 Mar 19;204(3):619-31. Epub 2007 Feb 26.

10.

STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils.

Panopoulos AD, Zhang L, Snow JW, Jones DM, Smith AM, El Kasmi KC, Liu F, Goldsmith MA, Link DC, Murray PJ, Watowich SS.

Blood. 2006 Dec 1;108(12):3682-90. Epub 2006 Aug 3.

11.

Enhanced replication of R5 HIV-1 over X4 HIV-1 in CD4(+)CCR5(+)CXCR4(+) T cells.

Roy AM, Schweighardt B, Eckstein LA, Goldsmith MA, McCune JM.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):267-75.

PMID:
16249699
12.

Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas.

Abraham N, Ma MC, Snow JW, Miners MJ, Herndier BG, Goldsmith MA.

Oncogene. 2005 Aug 4;24(33):5252-7.

PMID:
15870688
13.

Tissue-resident macrophages are productively infected ex vivo by primary X4 isolates of human immunodeficiency virus type 1.

Jayakumar P, Berger I, Autschbach F, Weinstein M, Funke B, Verdin E, Goldsmith MA, Keppler OT.

J Virol. 2005 Apr;79(8):5220-6.

14.

Transgenic bcl-2 is not sufficient to rescue all hematolymphoid defects in STAT5A/5B-deficient mice.

Snow JW, Abraham N, Ma MC, Bronson SK, Goldsmith MA.

Exp Hematol. 2003 Dec;31(12):1253-8.

PMID:
14662332
15.

Bone marrow transplant completely rescues hematolymphoid defects in STAT5A/5B-deficient mice.

Snow JW, Abraham N, Ma MC, Goldsmith MA.

Exp Hematol. 2003 Dec;31(12):1247-52.

PMID:
14662331
16.

Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice.

Snow JW, Abraham N, Ma MC, Herndier BG, Pastuszak AW, Goldsmith MA.

J Immunol. 2003 Nov 15;171(10):5042-50.

17.

Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages.

Sherman MP, de Noronha CM, Eckstein LA, Hataye J, Mundt P, Williams SA, Neidleman JA, Goldsmith MA, Greene WC.

J Virol. 2003 Jul;77(13):7582-9.

18.

In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells.

Jekle A, Keppler OT, De Clercq E, Schols D, Weinstein M, Goldsmith MA.

J Virol. 2003 May;77(10):5846-54.

19.

Contribution of the Box 1 and Box 2 motifs of cytokine receptors to Jak1 association and activation.

Usacheva A, Sandoval R, Domanski P, Kotenko SV, Nelms K, Goldsmith MA, Colamonici OR.

J Biol Chem. 2002 Dec 13;277(50):48220-6. Epub 2002 Oct 8.

20.

HIV entry: are all receptors created equal?

Goldsmith MA, Doms RW.

Nat Immunol. 2002 Aug;3(8):709-10. Epub 2002 Jul 1. No abstract available.

PMID:
12089511
21.

Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.

Jekle A, Schramm B, Jayakumar P, Trautner V, Schols D, De Clercq E, Mills J, Crowe SM, Goldsmith MA.

J Virol. 2002 Jul;76(14):6966-73.

22.
23.

Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1.

Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA.

J Exp Med. 2002 Mar 18;195(6):719-36.

24.

STAT5 promotes multilineage hematolymphoid development in vivo through effects on early hematopoietic progenitor cells.

Snow JW, Abraham N, Ma MC, Abbey NW, Herndier B, Goldsmith MA.

Blood. 2002 Jan 1;99(1):95-101.

PMID:
11756158
25.

HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells.

Eckstein DA, Sherman MP, Penn ML, Chin PS, De Noronha CM, Greene WC, Goldsmith MA.

J Exp Med. 2001 Nov 19;194(10):1407-19.

26.

HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues.

Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, Kreisberg JF, Roederer M, Sherman MP, Chin PS, Goldsmith MA.

Immunity. 2001 Oct;15(4):671-82.

27.

Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status.

Kreisberg JF, Kwa D, Schramm B, Trautner V, Connor R, Schuitemaker H, Mullins JI, van't Wout AB, Goldsmith MA.

J Virol. 2001 Sep;75(18):8842-7.

28.

Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1.

Keppler OT, Yonemoto W, Welte FJ, Patton KS, Iacovides D, Atchison RE, Ngo T, Hirschberg DL, Speck RF, Goldsmith MA.

J Virol. 2001 Sep;75(17):8063-73.

29.

Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses.

Chan SY, Empig CJ, Welte FJ, Speck RF, Schmaljohn A, Kreisberg JF, Goldsmith MA.

Cell. 2001 Jul 13;106(1):117-26.

30.

Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues.

Penn ML, Myers M, Eckstein DA, Liegler TJ, Hayden M, Mammano F, Clavel F, Deeks SG, Grant RM, Goldsmith MA.

AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):517-23.

PMID:
11350665
31.

Human immunodeficiency virus type 1 clade A and D neurotropism: molecular evolution, recombination, and coreceptor use.

Zhang K, Hawken M, Rana F, Welte FJ, Gartner S, Goldsmith MA, Power C.

Virology. 2001 Apr 25;283(1):19-30.

32.

Molecular function of the CD4 D1 domain in coreceptor-mediated entry by HIV type 1.

Esser U, Speck RF, Deen KC, Atchison RE, Sweet R, Goldsmith MA.

AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1845-54.

PMID:
11118070
33.

Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1.

Schramm B, Penn ML, Palacios EH, Grant RM, Kirchhoff F, Goldsmith MA.

J Virol. 2000 Oct;74(20):9594-600.

34.
35.

From the cell to the community: AIDS research in California. The University of California Universitywide AIDS Research Program annual meeting, February 2000.

Moss NE, Lemp G, Bluthenthal R, Goldsmith MA, Haubrich R, Kahn JO.

West J Med. 2000 Aug;173(2):119-24. No abstract available.

36.

Human immunodeficiency virus type 1 coreceptor preferences determine target T-cell depletion and cellular tropism in human lymphoid tissue.

Grivel JC, Penn ML, Eckstein DA, Schramm B, Speck RF, Abbey NW, Herndier B, Margolis L, Goldsmith MA.

J Virol. 2000 Jun;74(11):5347-51.

37.

Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses.

Chan SY, Speck RF, Ma MC, Goldsmith MA.

J Virol. 2000 May;74(10):4933-7.

38.

Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease.

Schramm B, Penn ML, Speck RF, Chan SY, De Clercq E, Schols D, Connor RI, Goldsmith MA.

J Virol. 2000 Jan;74(1):184-92.

39.

Genetic evidence for an additional factor required for erythropoietin-induced signal transduction.

Gaffen SL, Lai SY, Longmore GD, Liu KD, Goldsmith MA.

Blood. 1999 Jul 1;94(1):74-86.

PMID:
10381500
40.

A trans-receptor mechanism for infection of CD4-negative cells by human immunodeficiency virus type 1.

Speck RF, Esser U, Penn ML, Eckstein DA, Pulliam L, Chan SY, Goldsmith MA.

Curr Biol. 1999 May 20;9(10):547-50.

41.

Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.

Middleton SA, Barbone FP, Johnson DL, Thurmond RL, You Y, McMahon FJ, Jin R, Livnah O, Tullai J, Farrell FX, Goldsmith MA, Wilson IA, Jolliffe LK.

J Biol Chem. 1999 May 14;274(20):14163-9.

42.

Oligomerization and scaffolding functions of the erythropoietin receptor cytoplasmic tail.

Watowich SS, Liu KD, Xie X, Lai SY, Mikami A, Longmore GD, Goldsmith MA.

J Biol Chem. 1999 Feb 26;274(9):5415-21.

43.

V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1.

Chan SY, Speck RF, Power C, Gaffen SL, Chesebro B, Goldsmith MA.

J Virol. 1999 Mar;73(3):2350-8.

44.

CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue.

Penn ML, Grivel JC, Schramm B, Goldsmith MA, Margolis L.

Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):663-8.

45.

An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation.

Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, You Y, Liu KD, Goldsmith MA, He W, Krause CD, Pestka S, Jolliffe LK, Wilson IA.

Nat Struct Biol. 1998 Nov;5(11):993-1004.

PMID:
9808045
46.

Parallel evolution of CCR5-null phenotypes in humans and in a natural host of simian immunodeficiency virus.

Palacios E, Digilio L, McClure HM, Chen Z, Marx PA, Goldsmith MA, Grant RM.

Curr Biol. 1998 Jul 30-Aug 13;8(16):943-6.

47.

JAK/STAT signaling by cytokine receptors.

Liu KD, Gaffen SL, Goldsmith MA.

Curr Opin Immunol. 1998 Jun;10(3):271-8. Review.

PMID:
9638363
48.

Rabbit cells expressing human CD4 and human CCR5 are highly permissive for human immunodeficiency virus type 1 infection.

Speck RF, Penn ML, Wimmer J, Esser U, Hague BF, Kindt TJ, Atchison RE, Goldsmith MA.

J Virol. 1998 Jul;72(7):5728-34.

49.

Absence of cytokine receptor-dependent specificity in red blood cell differentiation in vivo.

Goldsmith MA, Mikami A, You Y, Liu KD, Thomas L, Pharr P, Longmore GD.

Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7006-11.

50.

Supplemental Content

Loading ...
Support Center